Revita® DMR evaluated for preventing weight regain after tirzepatide-induced 15% weight loss in obesity
Background
Achieving significant weight loss with GLP-1 receptor agonists like tirzepatide is highly effective for individuals with obesity. However, a major challenge is preventing weight regain once these medications are discontinued, often due to cost, side effects, or personal preference. This study addresses the critical unmet need for durable weight maintenance strategies beyond pharmacotherapy, exploring a procedural intervention to sustain metabolic improvements and prevent the rebound effect common after stopping anti-obesity medications.
Study Design
The REMAIN-1 pivotal study includes two cohorts: an open-label REVEAL-1 cohort and a randomized cohort. The randomized cohort enrolls patients with obesity (BMI 30-45 kg/m2) not currently on a GLP-1 drug. Participants are prescribed tirzepatide and titrated to achieve at least 15% total body weight loss. Upon reaching this target, tirzepatide is discontinued, and patients are randomized 2:1 to receive either Revita DMR or a sham procedure. A midpoint analysis will assess ~45 patients at three months, while the pivotal analysis will involve ~315 patients evaluating outcomes at six months and one year.
Results
This abstract describes the design of an ongoing Phase 3 clinical trial, and therefore, no efficacy or safety results are available yet. The study's primary objectives are to evaluate the safety and efficacy of Revita DMR for weight maintenance. The first co-primary endpoint will assess weight regain from the time of tirzepatide discontinuation in Revita DMR versus sham patients at six months. This aims to demonstrate a benefit of Revita DMR for weight maintenance after GLP-1 discontinuation. > The second co-primary endpoint evaluates a responder rate among the Revita DMR treated group at one year to demonstrate the durability of the Revita DMR procedure for weight maintenance after discontinuation of GLP-1-based therapy.
Key Findings
- Study aims to evaluate Revita DMR's safety and efficacy for weight maintenance post-tirzepatide discontinuation.
- First co-primary endpoint: weight regain at six months comparing Revita DMR to sham.
- Second co-primary endpoint: responder rate at one year for Revita DMR durability.
- Patients achieve >=15% weight loss on tirzepatide before randomization to Revita DMR or sham.
Why It Matters
This trial is highly significant as it investigates a potential non-pharmacological solution to the pervasive problem of weight regain after stopping GLP-1 agonists. If successful, Revita DMR could offer a durable, procedural option for individuals who have achieved substantial weight loss with tirzepatide but wish to discontinue medication. This could provide a crucial tool for long-term weight management, reducing reliance on continuous drug therapy and potentially improving sustained health outcomes. It addresses a major gap in current obesity treatment paradigms, offering a 'bridge' strategy to maintain benefits after initial pharmacologic intervention.
obesity
weight-loss
weight-maintenance
tirzepatide
revita-dmr
clinical-trial